A new study shows that tumor cells depleted of ARID1A — a protein that acts as a cancer suppressor — become highly sensitive to anticancer poly ADP ribose polymerase (PARP) inhibitor drugs after radiation treatment. The research could advance efforts to treat many human cancers with loss of ARID1A that are resistant to current standard treatments, the study team suggests.
Laboratory studies identify a potential way to treat human cancers with ARID1A mutations
Related Posts
Order Antibiotics online
June 8, 2024Buying antibiotics online
June 8, 2024How do antibiotics work?
June 8, 2024Flagyl: a beacon of hope in the fight against trichomoniasis
February 17, 2024
About admin
Now Dr. Jack Straw is in charge of the website, and organizes it so that medical care is available to everyone. In addition, he is an active member of the medical community, regularly attending international conferences and sharing his experience and knowledge.
Dr. Straw is not only a medical professional and website manager, but also a loving husband and father of his beautiful children.
View all posts by admin →